Great potential for European production of contrast agents and APIs
The effects of the Corona crisis make it evident that supply chains for pharmaceuticals that are dependent on third countries lead to critical shortages in supply or even cancellations. Particularly in the case of pharmaceutical raw materials, so-called active pharmaceutical ingredients (APIs), the industry is heavily dependent on China and India. As a result, there is a need to bring key production capacities back to Europe on a sustainable basis. SANOCHEMIA has the necessary prerequisites to further expand its expertise in this area within Austria. In the future, SANOCHEMIA intends to play a major role in the critical supply security of pharmaceuticals.
N-Chlortaurin from SANOCHEMIA as an innovative example
The current Corona pandemic is creating many concerns and question marks. At the same time, however, it also opens up strategic potential. SANOCHEMIA has been working for weeks on the active ingredient production of N-chlorotaurine (NCT). The substance is produced by the body itself during the defense against infections and supports the killing of infectious pathogens. The Medical University of Innsbruck has patented a process for the synthetic production of this substance, which SANOCHEMIA has developed to technical scale.
SANOCHEMIA is supporting the Medical University of Innsbruck in the preparation of a clinical trial on Covid-19, producing the active substance NCT for this planned study.
Already in the past, the Medical University of Innsbruck has published data on the very good tolerability of the substance.
SANOCHEMIA is a local manufacturer of pharmaceutical specialties
Particularly in the area of contract manufacturing of specialties, the company plans to offer itself to large pharmaceutical companies as a European ‘second source’ for the production of specialty active ingredients. At the site in Neufeld, Burgenland, for example, an active ingredient for a muscle relaxant is being manufactured. Many others could follow, as SANOCHEMIA has a general-purpose production facility, of which there are now only a handful in Austria.
In addition to its expertise in active pharmaceutical ingredients, SANOCHEMIA has many years of experience as a manufacturer of contrast media for diagnostic imaging in its largest business area. In this area, SANOCHEMIA acts both as a contract manufacturer (CMO) and as a supplier of some of the most established generic CT/XRT and MRI products on the market. A strong distribution network with local B2B partners ensures adequate market access in over 35 countries. Numerous new target markets are to be developed in the coming years.